Clinical-stage biotechnology company Spyre Therapeutics Inc (NASDAQ: SYRE) announced on Monday that it has commenced dosing of healthy volunteers in Phase 1 clinical trials of two investigational half-life extended anti-TL1A monoclonal antibodies.

The double blind, placebo-controlled single-ascending dose studies are being conducted in healthy volunteers, with each trial expected to enrol approximately 56 healthy adults.

Safety is the study's primary endpoint, with a secondary endpoint of pharmacokinetics (PK). Interim safety, PK and pharmacodynamic (PD) data from these trials are expected to be released in the second quarter of 2025.

Pending data from the Phase 1 trials, the company anticipates progressing the SPY002 programme into Phase 2 development in 2025.